- Home
- ARQQ vs ENGN Comparison
ARQQ vs ENGN Comparison
Compare ARQQ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARQQ | ENGN |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.3M | 379.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ARQQ | ENGN |
|---|---|---|
| Price | $24.37 | $8.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $60.00 | $22.71 |
| AVG Volume (30 Days) | 387.3K | ★ 528.5K |
| Earning Date | 12-09-2025 | 12-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,000.00 | N/A |
| Revenue This Year | $183.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.00 | $2.65 |
| 52 Week High | $62.00 | $11.14 |
Technical Indicators
Market Signals| Indicator | ARQQ | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 55.41 |
| Support Level | $27.50 | $7.77 |
| Resistance Level | $30.45 | $9.14 |
| Average True Range (ATR) | 2.37 | 0.60 |
| MACD | 0.32 | 0.06 |
| Stochastic Oscillator | 1.42 | 58.43 |
Price Performance
Historical ComparisonAbout ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.